ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

3:00PM-4:30PM: Abstract Number: 0517

Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus

Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

3:00PM-4:30PM: Abstract Number: 0508

Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood

Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0512

Development of CARRA Biologic Consensus Treatment Plans for Management of Refractory Moderate Juvenile Dermatomyositis

Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

3:00PM-4:00PM: Abstract Number: 0499

Drivers of Heterogeneity in Synovial Fibroblasts in Rheumatoid Arthritis

Abstracts: RA – Etiology and Pathogenesis

3:00PM-4:30PM: Abstract Number: 0521

Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis

Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

3:00PM-4:30PM: Abstract Number: 0509

Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0507

Gut Microbe Metabolite Short-Chain Fatty Acids May Associate with Development of Respiratory Involvement in Patients with Relapsing Polychondritis

Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0516

Identifying Current Assessment and Treatment Strategies in Juvenile Systemic Sclerosis: An International Effort to Improve Patient Outcomes

Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

3:00PM-4:30PM: Abstract Number: 0506

Immunophenotypic Categorization of Systemic Immune-mediated Diseases

Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0515

Juvenile Systemic Sclerosis Treatment Practices in an International Cohort and Comparison to Recent SHARE Consensus Guidelines

Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

3:00PM-4:00PM: Abstract Number: 0505

Longitudinal Trajectories of Central Pain Sensitization in People with or at Risk of Knee Osteoarthritis

Abstracts: Orthopedics, Low Back Pain, and Rehabilitation

3:00PM-4:30PM: Abstract Number: 0510

MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

3:00PM-4:30PM: Abstract Number: 0519

Myeloablation Followed by Hematopoietic Stem Cell Transplantation Leads to Long-term Normalization of Systemic Sclerosis Molecular Signatures

Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

3:00PM-4:30PM: Abstract Number: 0528

Nasal Epithelial Gene Expression Profiling Preceding Relapse in Patients with Granulomatosis with Polyangiitis

Abstracts: Vasculitis – ANCA-Associated

3:00PM-4:30PM: Abstract Number: 0525

Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial

Abstracts: Vasculitis – ANCA-Associated

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].